Sumichrast Martin A.

SEC source: 0001683168-26-004817 · ownership.xml · derivative · entry 2

Sumichrast Martin A. · CIK 0001427722 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1

Underlying: Common Stock · 221,878,595 shares

Expires 2027-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The securities shown are owned by Hawkeye Holdco LLC, of which the Reporting Person is the sole managing member. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001683168-26-004817 · ownership.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 242,017,296

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The securities shown are owned by Hawkeye Holdco LLC, of which the Reporting Person is the sole managing member. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001683168-26-004575 · ownership.xml · derivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1

Underlying: Common Stock · 221,878,595 shares

Expires 2027-03-31

F1 · ownership.nature: The securities shown are owned by Hawkeye Holdco LLC, of which the Reporting Person is the sole managing member. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001683168-26-004511 · ownership.xml · derivative · entry 2

Sumichrast Martin A. · CIK 0001427722 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 23,064,634 shares

Expires 2028-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The securities shown are owned by Hawkeye Holdco LLC, of which the Reporting Person is the sole managing member. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001683168-26-004511 · ownership.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 23,064,634

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The securities shown are owned by Hawkeye Holdco LLC, of which the Reporting Person is the sole managing member. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001654954-22-007214 · section16.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman, CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote

Disclosed balance after: 1,894,533

F1 · kind: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including the Sumichrast 2017 Family Trust ("Family Trust"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the Third Marking Period. On May 17, 2022 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the March 31, 2022 quarter of the Third Marketing Period had been achieved and the Issuer issued an aggregate of 458,877 shares of its common stock representing the March 31, 2022 Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 41,299 Earnout Shares to the Family Trust.

F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including the Sumichrast 2017 Family Trust ("Family Trust"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the Third Marking Period. On May 17, 2022 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the March 31, 2022 quarter of the Third Marketing Period had been achieved and the Issuer issued an aggregate of 458,877 shares of its common stock representing the March 31, 2022 Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 41,299 Earnout Shares to the Family Trust.

F2 · ownership.nature: Includes 250,000 shares of common stock held directly by the Reporting Person and 1,644,553 shares of common stock that are held of record by the Family Trust. The Reporting Person has the sole power to dispose of the shares of common stock held of record by the Family Trust. The Reporting Person has the sole right to vote 1,250,803 shares of common stock held by the Family Trust and the balance of 393,750 shares are subject to the terms of a Voting Trust Agreement dated February 26, 2020 between the Issuer and the Family Trust pursuant to which until such time as the unrestricted voting rights to these shares have vested, the voting rights to such shares are held by the independent chairman of the Audit Committee of the Issuer's board of directors who will vote such shares on any matter brought before the Issuer's shareholders in accordance with the recommendation of its board of directors. The voting rights to the 393,750 shares vest in equal portions on each of June 20, 2022 and December 20, 2023. The Reporting Person disclaims beneficial ownership of the securities held of record by the Family Trust except to the extent of his pecuniary interest therein.

SEC source: 0001654954-22-002405 · section16.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote 2

Disclosed balance after: 1,853,254

F1 · kind: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including the Sumichrast 2017 Family Trust ("Family Trust"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the Third Marking Period. On February __, 2022 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the December 31, 2021 quarter of the Third Marketing Period had been achieved and the Issuer issued an aggregate of 444,243 shares of its common stock representing the December 31, 2021 Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 39,982 Earnout Shares to the Family Trust.

F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including the Sumichrast 2017 Family Trust ("Family Trust"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the Third Marking Period. On February __, 2022 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the December 31, 2021 quarter of the Third Marketing Period had been achieved and the Issuer issued an aggregate of 444,243 shares of its common stock representing the December 31, 2021 Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 39,982 Earnout Shares to the Family Trust.

F2 · ownership.nature: Includes 250,000 shares of common stock held directly by the Reporting Person and 1,603,254 shares of common stock that are held of record by the Family Trust. The Reporting Person has the sole power to dispose of the shares of common stock held of record by the Family Trust. The Reporting Person has the sole right to vote 1,209,504 shares of common stock held by the Family Trust and the balance of 393,750 shares are subject to the terms of a Voting Trust Agreement dated February 26, 2020 between the Issuer and the Family Trust pursuant to which until such time as the unrestricted voting rights to these shares have vested, the voting rights to such shares are held by the independent chairman of the Audit Committee of the Issuer's board of directors who will vote such shares on any matter brought before the Issuer's shareholders in accordance with the recommendation of its board of directors. The voting rights to the 393,750 shares vest in equal portions on each of June 20, 2022 and December 20, 2023. The Reporting Person disclaims beneficial ownership of the securities held of record by the Family Trust except to the extent of his pecuniary interest therein.

SEC source: 0001654954-22-000045 · section16.xml · derivative · entry 3

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 250,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units were granted on April 19, 2021 and vested on January 1, 2022.

F4 · derivative.expiration_date: The restricted stock units were granted on April 19, 2021 and vested on January 1, 2022.

SEC source: 0001654954-22-000045 · section16.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents shares of common stock issued upon vesting of restricted stock units on January 1, 2022.

SEC source: 0001654954-21-013625 · section16.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,563,272

F1 · kind: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including the Sumichrast 2017 Family Trust ("Family Trust"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the Third Marking Period. On December 28, 2021 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the September 30, 2021 quarter within the Third Marking Period had been achieved and the Issuer issued an aggregate of 466,713 shares of its common stock representing the September 30, 2021 quarter of the Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement. Included in this issuance was the issuance of 42,004 Earnout Shares to the Family Trust.

F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including the Sumichrast 2017 Family Trust ("Family Trust"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the Third Marking Period. On December 28, 2021 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the September 30, 2021 quarter within the Third Marking Period had been achieved and the Issuer issued an aggregate of 466,713 shares of its common stock representing the September 30, 2021 quarter of the Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement. Included in this issuance was the issuance of 42,004 Earnout Shares to the Family Trust.

F2 · ownership.nature: Represents shares of common stock that are held of record by the Family Trust. The Reporting Person has the sole power to dispose of the shares of common stock held of record by the Family Trust. The Reporting Person has the sole right to vote 1,169,522 shares of common stock held by the Family Trust and the balance of 393,750 shares are subject to the terms of a Voting Trust Agreement dated February 26, 2020 between the Issuer and the Family Trust pursuant to which until such time as the unrestricted voting rights to these shares have vested, the voting rights to such shares are held by the independent chairman of the Audit Committee of the Issuer's board of directors who will vote such shares on any matter brought before the Issuer's shareholders in accordance with the recommendation of its board of directors. The voting rights to the 393,750 shares vest in equal portions on each of June 20, 2022 and December 20, 2023. The Reporting Person disclaims beneficial ownership of the securities held of record by the Family Trust except to the extent of his pecuniary interest therein.

SEC source: 0001654954-21-009235 · section16.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,521,244

F1 · kind: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including the Sumichrast 2017 Family Trust ("Family Trust"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the Third Marking Period. On August 16, 2021 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the June 30, 2021 quarter within the Third Marking Period had been achieved and the Issuer issued an aggregate of 503,275 shares of its common stock representing the June 30, 2021 quarter of the Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement. Included in this issuance was the issuance of 45,295 Earnout Shares to the Family Trust.

F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including the Sumichrast 2017 Family Trust ("Family Trust"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the Third Marking Period. On August 16, 2021 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the June 30, 2021 quarter within the Third Marking Period had been achieved and the Issuer issued an aggregate of 503,275 shares of its common stock representing the June 30, 2021 quarter of the Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement. Included in this issuance was the issuance of 45,295 Earnout Shares to the Family Trust.

F2 · ownership.nature: Represents shares of common stock that are held of record by the Family Trust. The Reporting Person has the sole power to dispose of the shares of common stock held of record by the Family Trust. The Reporting Person has the sole right to vote 1,127,494 shares of common stock held by the Family Trust and the balance of 393,750 shares are subject to the terms of a Voting Trust Agreement dated February 26, 2020 between the Issuer and the Family Trust pursuant to which until such time as the unrestricted voting rights to these shares have vested, the voting rights to such shares are held by the independent chairman of the Audit Committee of the Issuer's board of directors who will vote such shares on any matter brought before the Issuer's shareholders in accordance with the recommendation of its board of directors. The voting rights to the 393,750 shares vest in equal portions on each of June 20, 2022 and December 20, 2023. The Reporting Person disclaims beneficial ownership of the securities held of record by the Family Trust except to the extent of his pecuniary interest therein.

SEC source: 0001654954-21-006009 · section16.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,475,949

F1 · kind: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months, and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including the Sumichrast 2017 Family Trust ("Family Trust"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the third marking period to change the determination of the aggregate net revenues within the third marking period to a quarterly basis for each of the six fiscal quarters within the third marking period, beginning with the quarter ended March 31, 2021, instead of following third marking period end date which was 18 months after the beginning of the third marking period. On May 14, 2021 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the March 31, 2021 quarter within the third marking period had been achieved and the Issuer issued an aggregate of 572,278 shares of its common stock representing the March 31, 2021 quarter of the third marking period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 50,605 Earnout Shares to the Family Trust.

F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months, and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including the Sumichrast 2017 Family Trust ("Family Trust"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the third marking period to change the determination of the aggregate net revenues within the third marking period to a quarterly basis for each of the six fiscal quarters within the third marking period, beginning with the quarter ended March 31, 2021, instead of following third marking period end date which was 18 months after the beginning of the third marking period. On May 14, 2021 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the March 31, 2021 quarter within the third marking period had been achieved and the Issuer issued an aggregate of 572,278 shares of its common stock representing the March 31, 2021 quarter of the third marking period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 50,605 Earnout Shares to the Family Trust.

F2 · ownership.nature: Represents shares of common stock that are held of record by the Family Trust. The Reporting Person has the sole power to dispose of the shares of common stock held of record by the Family Trust. The Reporting Person has the sole right to vote 1,082,199 shares of common stock held by the Family Trust and the balance of 393,750 shares are subject to the terms of a Voting Trust Agreement dated February 26, 2020 between the Issuer and the Family Trust pursuant to which until such time as the unrestricted voting rights to these shares have vested, the voting rights to such shares are held by the independent chairman of the Audit Committee of the Issuer's board of directors who will vote such shares on any matter brought before the Issuer's shareholders in accordance with the recommendation of its board of directors. The voting rights to the 393,750 shares vest in equal portions on each of June 20, 2022 and December 20, 2023. The Reporting Person disclaims beneficial ownership of the securities held of record by the Family Trust except to the extent of his pecuniary interest therein.

SEC source: 0001654954-21-004492 · section16.xml · derivative · entry 6

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common stock · 250,000 shares

Expires 2024-01-01

F2 · security: Represents grants of restricted stock awards to the Reporting Person under the 2021 Plan pursuant to the terms and conditions of the Sumichrast Employment Agreement.

SEC source: 0001654954-21-004492 · section16.xml · derivative · entry 5

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common stock · 250,000 shares

Expires 2023-01-01

F2 · security: Represents grants of restricted stock awards to the Reporting Person under the 2021 Plan pursuant to the terms and conditions of the Sumichrast Employment Agreement.

SEC source: 0001654954-21-004492 · section16.xml · derivative · entry 4

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common stock · 250,000 shares

Expires 2022-01-01

F2 · security: Represents grants of restricted stock awards to the Reporting Person under the 2021 Plan pursuant to the terms and conditions of the Sumichrast Employment Agreement.

SEC source: 0001654954-21-004492 · section16.xml · derivative · entry 3

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common stock · 250,000 shares

Expires 2029-01-01

F1 · security: Represents grants of stock options to the Reporting Person under the Issuer's 2021 Equity Compensation Plan (the "2021 Plan") pursuant to the terms and conditions of the Amended and Restated Executive Employment Agreement dated April 19, 2012 by and between the Issuer and the Reporting Person (the "Sumichrast Employment Agreement").

SEC source: 0001654954-21-004492 · section16.xml · derivative · entry 2

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common stock · 250,000 shares

Expires 2028-01-01

F1 · security: Represents grants of stock options to the Reporting Person under the Issuer's 2021 Equity Compensation Plan (the "2021 Plan") pursuant to the terms and conditions of the Amended and Restated Executive Employment Agreement dated April 19, 2012 by and between the Issuer and the Reporting Person (the "Sumichrast Employment Agreement").

SEC source: 0001654954-21-004492 · section16.xml · derivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common stock · 250,000 shares

Expires 2027-01-01

F1 · security: Represents grants of stock options to the Reporting Person under the Issuer's 2021 Equity Compensation Plan (the "2021 Plan") pursuant to the terms and conditions of the Amended and Restated Executive Employment Agreement dated April 19, 2012 by and between the Issuer and the Reporting Person (the "Sumichrast Employment Agreement").

SEC source: 0001654954-21-002741 · section16.xml · nonDerivative · entry 2

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,425,344

F1 · ownership.nature: The number of shares of common stock sold by the Reporting Person in the reported transactions were owned of record by the Sumichrast 2017 Family Trust (the "Family Trust"). The Reporting Person has voting and dispositive control over securities owned of record by the Family Trust. The Reporting Person disclaims beneficial ownership of the securities held of record by this entity except to the extent of his pecuniary interest therein. The Reporting Person has the sole power to dispose of the shares of common stock held of record by the Family Trust. The Reporting Person has the sole right to vote 1,031,594 shares of common stock held by the Family Trust and the balance of 393,750 shares are subject to the terms of a Voting Trust Agreement dated February 26, 2020 between the Issuer and the Family Trust pursuant to which until such time as the unrestricted voting rights to these shares have vested, the voting rights to such shares are held by the independent chairman of the Audit Committee of the Issuer's board of directors who will vote such shares on any matter brought before the Issuer's shareholders in accordance with the recommendation of its board of directors. The voting rights to the 393,750 shares vest in equal portions on each of June 20, 2022 and December 20, 2023.

SEC source: 0001654954-21-002741 · section16.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,490,837

F1 · ownership.nature: The number of shares of common stock sold by the Reporting Person in the reported transactions were owned of record by the Sumichrast 2017 Family Trust (the "Family Trust"). The Reporting Person has voting and dispositive control over securities owned of record by the Family Trust. The Reporting Person disclaims beneficial ownership of the securities held of record by this entity except to the extent of his pecuniary interest therein. The Reporting Person has the sole power to dispose of the shares of common stock held of record by the Family Trust. The Reporting Person has the sole right to vote 1,031,594 shares of common stock held by the Family Trust and the balance of 393,750 shares are subject to the terms of a Voting Trust Agreement dated February 26, 2020 between the Issuer and the Family Trust pursuant to which until such time as the unrestricted voting rights to these shares have vested, the voting rights to such shares are held by the independent chairman of the Audit Committee of the Issuer's board of directors who will vote such shares on any matter brought before the Issuer's shareholders in accordance with the recommendation of its board of directors. The voting rights to the 393,750 shares vest in equal portions on each of June 20, 2022 and December 20, 2023.

SEC source: 0001654954-21-002572 · section16.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,550,344

F1 · kind: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months (the "Second Marking Period"), 42 calendar months, and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including the Sumichrast 2017 Family Trust ("Family Trust"), on a pro rata basis. On March 8, 2021 in accordance with the terms of the Merger Agreement the Issuer determined that the net revenue criteria for the Second Marking Period had been achieved and the Issuer issued an aggregate of 3,348,250 shares of its common stock representing the Second Marking Period Earnout Shares which were earned under the terms of the Merger Agreement. Included in this issuance was the issuance of 301,343 Earnout Shares to the Family Trust.

F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months (the "Second Marking Period"), 42 calendar months, and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including the Sumichrast 2017 Family Trust ("Family Trust"), on a pro rata basis. On March 8, 2021 in accordance with the terms of the Merger Agreement the Issuer determined that the net revenue criteria for the Second Marking Period had been achieved and the Issuer issued an aggregate of 3,348,250 shares of its common stock representing the Second Marking Period Earnout Shares which were earned under the terms of the Merger Agreement. Included in this issuance was the issuance of 301,343 Earnout Shares to the Family Trust.

F2 · ownership.nature: Represents shares of common stock that are held of record by the Family Trust. The Reporting Person has the sole power to dispose of the shares of common stock held of record by the Family Trust. The Reporting Person has the sole right to vote 1,156,594 shares of common stock held by the Family Trust and the balance of 393,750 shares are subject to the terms of a Voting Trust Agreement dated February 26, 2020 between the Issuer and the Family Trust pursuant to which until such time as the unrestricted voting rights to these shares have vested, the voting rights to such shares are held by the independent chairman of the Audit Committee of the Issuer's board of directors who will vote such shares on any matter brought before the Issuer's shareholders in accordance with the recommendation of its board of directors. The voting rights to the 393,750 shares vest in equal portions on each of June 20, 2022 and December 20, 2023. The Reporting Person disclaims beneficial ownership of the securities held of record by the Family Trust except to the extent of his pecuniary interest therein.

SEC source: 0001654954-21-001934 · section16.xml · nonDerivative · entry 3

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · ownership.nature: The number of shares of common stock sold by the Reporting Person in the reported transactions were owned of record by SFTI, LLC. The Reporting Person in his position at SFTI, LLC has the right to direct the vote and disposition of securities owned by SFTI, LLC. The Reporting Person disclaims beneficial ownership of the securities held of record by SFTI, LLC except to the extent of his pecuniary interest therein.

SEC source: 0001654954-21-002522 · section16.xml · nonDerivative · entry 3

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · ownership.nature: The number of shares of common stock sold by the Reporting Person in the reported transactions were owned of record by SFTI, LLC. The Reporting Person in his position at SFTI, LLC has the right to direct the vote and disposition of securities owned by SFTI, LLC. The Reporting Person disclaims beneficial ownership of the securities held of record by SFTI, LLC except to the extent of his pecuniary interest therein.

SEC source: 0001654954-21-001934 · section16.xml · nonDerivative · entry 2

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 240,035

F1 · ownership.nature: The number of shares of common stock sold by the Reporting Person in the reported transactions were owned of record by SFTI, LLC. The Reporting Person in his position at SFTI, LLC has the right to direct the vote and disposition of securities owned by SFTI, LLC. The Reporting Person disclaims beneficial ownership of the securities held of record by SFTI, LLC except to the extent of his pecuniary interest therein.

SEC source: 0001654954-21-002522 · section16.xml · nonDerivative · entry 2

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 240,035

F1 · ownership.nature: The number of shares of common stock sold by the Reporting Person in the reported transactions were owned of record by SFTI, LLC. The Reporting Person in his position at SFTI, LLC has the right to direct the vote and disposition of securities owned by SFTI, LLC. The Reporting Person disclaims beneficial ownership of the securities held of record by SFTI, LLC except to the extent of his pecuniary interest therein.

SEC source: 0001654954-21-001934 · section16.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 353,139

F1 · ownership.nature: The number of shares of common stock sold by the Reporting Person in the reported transactions were owned of record by SFTI, LLC. The Reporting Person in his position at SFTI, LLC has the right to direct the vote and disposition of securities owned by SFTI, LLC. The Reporting Person disclaims beneficial ownership of the securities held of record by SFTI, LLC except to the extent of his pecuniary interest therein.

SEC source: 0001654954-21-002522 · section16.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 353,139

F1 · ownership.nature: The number of shares of common stock sold by the Reporting Person in the reported transactions were owned of record by SFTI, LLC. The Reporting Person in his position at SFTI, LLC has the right to direct the vote and disposition of securities owned by SFTI, LLC. The Reporting Person disclaims beneficial ownership of the securities held of record by SFTI, LLC except to the extent of his pecuniary interest therein.

SEC source: 0001654954-20-002075 · section16.xml · nonDerivative · entry 2

Sumichrast Martin A. · CIK 0001427722 · Director · CO-CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,644,601

F3 · kind: Pursuant to the terms of the Merger Agreement, CBDH was also entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock (the "Earnout Shares") as part of the merger consideration upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months (the "First Marking Period"), 24 calendar months (the "Second Marking Period"), 42 calendar months (the "Third Marking Period"), and 59 calendar months (the "Fourth Marking Period"). Pursuant to the terms of the CBDH Distribution Agreement, CBDH distributed the Earnout Rights to its members on a pro rata basis. On February 27, 2020 in accordance with the terms of the Merger Agreement the Issuer determined that the net revenue criteria for the First Marking Period had been achieved and an aggregate of 5,127,792 Earnout Shares were to be issued (the "First Marking Period Earnout Shares"). After giving effect to the First Marking Period Earnout Shares, Earnout Rights to an aggregate of 10,122,208 Earnout Shares (the "Remaining Earnout Rights") remain under the terms of the Merger Agreement. Represents the pro rata number of the First Marking Period Earnout Shares issued to the Reporting Person.

F2 · price: Under the terms of the Merger Agreement the Second Tranche Shares were subject to a Voting Proxy Agreement pending the vesting of unrestricted voting rights, of which unrestricted voting rights to an aggregate of 2,187,500 shares vested on December 20, 2019. Pursuant to the Voting Proxy Agreement, the voting rights to the shares of the Issuer's common stock for which unrestricted voting rights have not yet vested are held by the independent chairman of the Audit Committee of the Issuer's board of directors who will vote such shares on any matter brought before the Issuer's shareholders in accordance with the recommendation of its board of directors. On February 26, 2020, in connection with the CBDH Distribution Agreement, the CBDH members including the Reporting Person entered into similar Voting Proxy Agreements with the Issuer. The Reporting Person holds unrestricted voting rights to 196,875 Second Tranche Shares, and the remaining 590,625 Second Tranche Shares distributed to the Reporting Person are subject to the Voting Proxy Agreement, with unrestricted voting rights thereto vesting in equal thirds on December 20, 2020, June 20, 2022 and December 20, 2023.

F2 · ownership.nature: Under the terms of the Merger Agreement the Second Tranche Shares were subject to a Voting Proxy Agreement pending the vesting of unrestricted voting rights, of which unrestricted voting rights to an aggregate of 2,187,500 shares vested on December 20, 2019. Pursuant to the Voting Proxy Agreement, the voting rights to the shares of the Issuer's common stock for which unrestricted voting rights have not yet vested are held by the independent chairman of the Audit Committee of the Issuer's board of directors who will vote such shares on any matter brought before the Issuer's shareholders in accordance with the recommendation of its board of directors. On February 26, 2020, in connection with the CBDH Distribution Agreement, the CBDH members including the Reporting Person entered into similar Voting Proxy Agreements with the Issuer. The Reporting Person holds unrestricted voting rights to 196,875 Second Tranche Shares, and the remaining 590,625 Second Tranche Shares distributed to the Reporting Person are subject to the Voting Proxy Agreement, with unrestricted voting rights thereto vesting in equal thirds on December 20, 2020, June 20, 2022 and December 20, 2023.

F4 · ownership.nature: Includes securities held of record by SFTI, LLC, an entity over which the Reporting Person has voting and dispositive control, and a family trust. The Reporting Person disclaims beneficial ownership of securities held of record by SFTI, LLC and the family trust except to the extent of his pecuniary interest therein.

SEC source: 0001654954-20-002075 · section16.xml · derivative · entry 3

Sumichrast Martin A. · CIK 0001427722 · Director · CO-CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 910,999

Underlying: Common Stock · 910,999 shares

Expires not disclosed

F3 · derivative.exercise_price: Pursuant to the terms of the Merger Agreement, CBDH was also entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock (the "Earnout Shares") as part of the merger consideration upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months (the "First Marking Period"), 24 calendar months (the "Second Marking Period"), 42 calendar months (the "Third Marking Period"), and 59 calendar months (the "Fourth Marking Period"). Pursuant to the terms of the CBDH Distribution Agreement, CBDH distributed the Earnout Rights to its members on a pro rata basis. On February 27, 2020 in accordance with the terms of the Merger Agreement the Issuer determined that the net revenue criteria for the First Marking Period had been achieved and an aggregate of 5,127,792 Earnout Shares were to be issued (the "First Marking Period Earnout Shares"). After giving effect to the First Marking Period Earnout Shares, Earnout Rights to an aggregate of 10,122,208 Earnout Shares (the "Remaining Earnout Rights") remain under the terms of the Merger Agreement. Represents the pro rata number of the First Marking Period Earnout Shares issued to the Reporting Person.

F5 · derivative.exercise_price: Represents the pro rata number of Remaining Earnout Rights distributed to the Reporting Person pursuant to the terms of the CBDH Distribution Agreement.

F3 · kind: Pursuant to the terms of the Merger Agreement, CBDH was also entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock (the "Earnout Shares") as part of the merger consideration upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months (the "First Marking Period"), 24 calendar months (the "Second Marking Period"), 42 calendar months (the "Third Marking Period"), and 59 calendar months (the "Fourth Marking Period"). Pursuant to the terms of the CBDH Distribution Agreement, CBDH distributed the Earnout Rights to its members on a pro rata basis. On February 27, 2020 in accordance with the terms of the Merger Agreement the Issuer determined that the net revenue criteria for the First Marking Period had been achieved and an aggregate of 5,127,792 Earnout Shares were to be issued (the "First Marking Period Earnout Shares"). After giving effect to the First Marking Period Earnout Shares, Earnout Rights to an aggregate of 10,122,208 Earnout Shares (the "Remaining Earnout Rights") remain under the terms of the Merger Agreement. Represents the pro rata number of the First Marking Period Earnout Shares issued to the Reporting Person.

F3 · price: Pursuant to the terms of the Merger Agreement, CBDH was also entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock (the "Earnout Shares") as part of the merger consideration upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months (the "First Marking Period"), 24 calendar months (the "Second Marking Period"), 42 calendar months (the "Third Marking Period"), and 59 calendar months (the "Fourth Marking Period"). Pursuant to the terms of the CBDH Distribution Agreement, CBDH distributed the Earnout Rights to its members on a pro rata basis. On February 27, 2020 in accordance with the terms of the Merger Agreement the Issuer determined that the net revenue criteria for the First Marking Period had been achieved and an aggregate of 5,127,792 Earnout Shares were to be issued (the "First Marking Period Earnout Shares"). After giving effect to the First Marking Period Earnout Shares, Earnout Rights to an aggregate of 10,122,208 Earnout Shares (the "Remaining Earnout Rights") remain under the terms of the Merger Agreement. Represents the pro rata number of the First Marking Period Earnout Shares issued to the Reporting Person.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, CBDH was also entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock (the "Earnout Shares") as part of the merger consideration upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months (the "First Marking Period"), 24 calendar months (the "Second Marking Period"), 42 calendar months (the "Third Marking Period"), and 59 calendar months (the "Fourth Marking Period"). Pursuant to the terms of the CBDH Distribution Agreement, CBDH distributed the Earnout Rights to its members on a pro rata basis. On February 27, 2020 in accordance with the terms of the Merger Agreement the Issuer determined that the net revenue criteria for the First Marking Period had been achieved and an aggregate of 5,127,792 Earnout Shares were to be issued (the "First Marking Period Earnout Shares"). After giving effect to the First Marking Period Earnout Shares, Earnout Rights to an aggregate of 10,122,208 Earnout Shares (the "Remaining Earnout Rights") remain under the terms of the Merger Agreement. Represents the pro rata number of the First Marking Period Earnout Shares issued to the Reporting Person.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, CBDH was also entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock (the "Earnout Shares") as part of the merger consideration upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months (the "First Marking Period"), 24 calendar months (the "Second Marking Period"), 42 calendar months (the "Third Marking Period"), and 59 calendar months (the "Fourth Marking Period"). Pursuant to the terms of the CBDH Distribution Agreement, CBDH distributed the Earnout Rights to its members on a pro rata basis. On February 27, 2020 in accordance with the terms of the Merger Agreement the Issuer determined that the net revenue criteria for the First Marking Period had been achieved and an aggregate of 5,127,792 Earnout Shares were to be issued (the "First Marking Period Earnout Shares"). After giving effect to the First Marking Period Earnout Shares, Earnout Rights to an aggregate of 10,122,208 Earnout Shares (the "Remaining Earnout Rights") remain under the terms of the Merger Agreement. Represents the pro rata number of the First Marking Period Earnout Shares issued to the Reporting Person.

F4 · ownership.nature: Includes securities held of record by SFTI, LLC, an entity over which the Reporting Person has voting and dispositive control, and a family trust. The Reporting Person disclaims beneficial ownership of securities held of record by SFTI, LLC and the family trust except to the extent of his pecuniary interest therein.

SEC source: 0001654954-20-002075 · section16.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · CO-CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,183,100

F1 · kind: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), an aggregate of 8,750,000 shares of the Issuer's common stock (the "Second Tranche Shares") were issued to CBD Holding, LLC ("CBDH") in April 2019 as partial consideration under the terms of the Merger Agreement. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement (the "CBDH Distribution Agreement"), CBDH distributed the Second Tranche Shares to its members on a pro rata basis. Represents the pro rata number of Second Tranche Shares distributed to the Reporting Person by CBDH.

F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), an aggregate of 8,750,000 shares of the Issuer's common stock (the "Second Tranche Shares") were issued to CBD Holding, LLC ("CBDH") in April 2019 as partial consideration under the terms of the Merger Agreement. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement (the "CBDH Distribution Agreement"), CBDH distributed the Second Tranche Shares to its members on a pro rata basis. Represents the pro rata number of Second Tranche Shares distributed to the Reporting Person by CBDH.

F2 · ownership.nature: Under the terms of the Merger Agreement the Second Tranche Shares were subject to a Voting Proxy Agreement pending the vesting of unrestricted voting rights, of which unrestricted voting rights to an aggregate of 2,187,500 shares vested on December 20, 2019. Pursuant to the Voting Proxy Agreement, the voting rights to the shares of the Issuer's common stock for which unrestricted voting rights have not yet vested are held by the independent chairman of the Audit Committee of the Issuer's board of directors who will vote such shares on any matter brought before the Issuer's shareholders in accordance with the recommendation of its board of directors. On February 26, 2020, in connection with the CBDH Distribution Agreement, the CBDH members including the Reporting Person entered into similar Voting Proxy Agreements with the Issuer. The Reporting Person holds unrestricted voting rights to 196,875 Second Tranche Shares, and the remaining 590,625 Second Tranche Shares distributed to the Reporting Person are subject to the Voting Proxy Agreement, with unrestricted voting rights thereto vesting in equal thirds on December 20, 2020, June 20, 2022 and December 20, 2023.

F4 · ownership.nature: Includes securities held of record by SFTI, LLC, an entity over which the Reporting Person has voting and dispositive control, and a family trust. The Reporting Person disclaims beneficial ownership of securities held of record by SFTI, LLC and the family trust except to the extent of his pecuniary interest therein.

SEC source: 0001654954-20-000513 · section16.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · CO-CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 395,600

F1 · ownership.nature: The number of shares of common stock beneficially owned by Mr. Sumichrast represents shares held of record by SFT1 LLC. Mr. Sumichrast has voting and dispositive control over securities held by SFT1 LLC. Mr. Sumichrast disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001654954-19-013869 · section16.xml · derivative · entry 3

Sumichrast Martin A. · CIK 0001427722 · Director · CO-CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,666

Underlying: common stock · 46,666 shares

Expires 2024-12-11

SEC source: 0001654954-19-013869 · section16.xml · derivative · entry 2

Sumichrast Martin A. · CIK 0001427722 · Director · CO-CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,667

Underlying: common stock · 46,667 shares

Expires 2024-12-11

SEC source: 0001654954-19-013869 · section16.xml · derivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · CO-CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,667

Underlying: common stock · 46,667 shares

Expires 2024-12-11

SEC source: 0001654954-19-002497 · section16.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 270,600

F1 · shares: Represents the private sale of shares by Stone Street Partners, LLC. Mr. Sumichrast in his position at Stone Street Partners, LLC has the right to direct the vote and disposition of securities owned by Stone Street Partners, LLC.

F2 · ownership.nature: The number of shares beneficially owned by Mr. Sumichrast includes 270,600 shares held of record by Washington Capital LLC. Mr. Sumichrast has voting and dispositive control over securities owned by Washington Capital LLC. Mr. Sumichrast disclaims beneficial ownership of the securities held of record by each of these entities except to the extent of his pecuniary interest therein.

SEC source: 0001654954-19-001902 · section16.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote

Disclosed balance after: 596,434

F1 · shares: Represents the private sale of shares by Stone Street Partners, LLC. Mr. Sumichrast in his position at Stone Street Partners, LLC has the right to direct the vote and disposition of securities owned by Stone Street Partners, LLC.

F2 · ownership.nature: The number of shares beneficially owned by Mr. Sumichrast includes (i) 325,834 shares held of record by Stone Street Partners, LLC and (ii) 270,600 shares held of record by Washington Capital LLC. Mr. Sumichrast in his position at Stone Street Partners, LLC has the right to direct the vote and disposition of securities owned by Stone Street Partners, LLC. Mr. Sumichrast has voting and dispositive control over securities owned by Washington Capital LLC. Mr. Sumichrast disclaims beneficial ownership of the securities held of record by each of these entities except to the extent of his pecuniary interest therein.

SEC source: 0001654954-18-007315 · section16.xml · nonDerivative · entry 2

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 746,434

F2 · ownership.nature: On July 1, 2018 Washington Capital LLC transferred 150,000 shares of the issuer's common stock to Stone Street Partners, LLC. The number of shares beneficially owned by Mr. Sumichrast includes (i) 475,834 shares held of record by Stone Street Partners, LLC and (ii) 270,600 shares held of record by Washington Capital LLC. Mr. Sumichrast in his position at Stone Street Partners, LLC has the right to direct the vote and disposition of securities owned by Stone Street Partners, LLC. Mr. Sumichrast has voting and dispositive control over securities owned by Washington Capital LLC. Mr. Sumichrast disclaims beneficial ownership of the securities held of record by each of these entities except to the extent of his pecuniary interest therein.

SEC source: 0001654954-18-007315 · section16.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 746,434

F1 · ownership.nature: On July 1, 2018 Mr. Sumichrast contributed 150,000 shares of the issuer's common stock held by him individually to Washington Capital, LLC, a limited liability company of which he is the manager, in exchange for membership interests in this entity. After this transaction, the number of shares beneficially owned by Mr. Sumichrast included (i) 325,834 shares held of record by Stone Street Partners, LLC and (ii) 420,600 shares held of record by Washington Capital LLC. Mr. Sumichrast in his position at Stone Street Partners, LLC has the right to direct the vote and disposition of securities owned by Stone Street Partners, LLC. Mr. Sumichrast has voting and dispositive control over securities owned by Washington Capital LLC. Mr. Sumichrast disclaims beneficial ownership of the securities held of record by each of these entities except to the extent of his pecuniary interest therein.

SEC source: 0001654954-18-000057 · section16.xml · derivative · entry 2

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: common stock · 150,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents vesting of restricted stock grant.

F3 · derivative.expiration_date: No expiration date.

SEC source: 0001654954-18-000057 · section16.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 746,434

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents vesting of restricted stock grant.

F2 · ownership.nature: The number of shares beneficially owned by Mr. Sumichrast includes (i) 325,834 shares held of record by Stone Street Partners, LLC and (ii) 270,600 shares held of record by Washington Capital LLC. Mr. Sumichrast in his position at Stone Street Partners, LLC has the right to direct the vote and disposition of securities owned by Stone Street Partners, LLC. Mr. Sumichrast has voting and dispositive control over securities owned by Washington Capital LLC. Mr. Sumichrast disclaims beneficial ownership of the securities held of record by each of these entities except to the extent of his pecuniary interest therein.

SEC source: 0001225208-17-001837 · doc4.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Trustee

10b5-1 filing: Not disclosed

Ownership: Indirect · By Stone Street Partners, LLC

Disclosed balance after: 0

F1 · ownership.nature: The Reporting Person is a Managing Partner of Stone Street Partners, LLC ("the firm"), and therefore is in a position to determine the investment and voting decisions made by the firm. Accordingly, the Reporting Person may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the shares beneficially owned by the firm. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. The Reporting Person is a trustee of the Issuer. Stone Street Partners, LLC was formerly named Siskey Capital, LLC.